» Articles » PMID: 804350

Quantitative Prediction of Drug Toxicity in Humans from Toxicology in Small and Large Animals

Overview
Journal Cancer Res
Specialty Oncology
Date 1975 May 1
PMID 804350
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

The mouse, dog, and monkey toxicity data on 30 drugs was retrospectively analyzed in comparison with the actual clinical dose schedules used in man. Animal dose schedules were converted to the human schedule and comparisons were made of the human dose versus the large animal toxic dose low, toxic dose high, and lethal dose, the lethal doses for 10% and 90% of normal mice, and the optimal dose in tumor-bearing mice. If the starting dose in Phase 1 clinical trials had been selected by calculating one-third of the toxic dose low (in mg/sq m) in the most sensitive large animal species, 5 of the 30 drugs would have produced significant toxicity in the first patient. The lethal doses for 10 and 90% of normal mice and the optimal dose in L1210-bearing mice were found to offer good quantitative prediction of human toxicity. Determination of a safe and practical starting dose for Phase 1 studies should take into account not only dog and monkey data but also toxicology data in normal and tumor-bearing mice.

Citing Articles

Iron Overload Resulting from the Chronic Oral Administration of Ferric Citrate Impairs Intestinal Immune and Barrier in Mice.

Luo Q, Lao C, Huang C, Xia Y, Ma W, Liu W Biol Trace Elem Res. 2020; 199(3):1027-1036.

PMID: 32468223 DOI: 10.1007/s12011-020-02218-4.


Iron overload resulting from the chronic oral administration of ferric citrate induces parkinsonism phenotypes in middle-aged mice.

Huang C, Ma W, Luo Q, Shi L, Xia Y, Lao C Aging (Albany NY). 2019; 11(21):9846-9861.

PMID: 31699955 PMC: 6874424. DOI: 10.18632/aging.102433.


Tolerability of a rapid-escalation vinblastine-prednisolone protocol in dogs with mast cell tumours.

Serra Varela J, Pecceu E, Handel I, Lawrence J Vet Med Sci. 2017; 2(4):266-280.

PMID: 29067202 PMC: 5645846. DOI: 10.1002/vms3.42.


Use of a failure probability constraint to suggest an initial dose in a phase I cancer clinical trial.

Chang S, Chang C, Lin Y, Lian I, Fann C J Food Drug Anal. 2017; 22(4):556-562.

PMID: 28911474 PMC: 9355001. DOI: 10.1016/j.jfda.2013.12.004.


Folate-targeted pH-responsive calcium zoledronate nanoscale metal-organic frameworks: Turning a bone antiresorptive agent into an anticancer therapeutic.

Au K, Satterlee A, Min Y, Tian X, Kim Y, Caster J Biomaterials. 2016; 82:178-93.

PMID: 26763733 PMC: 4728024. DOI: 10.1016/j.biomaterials.2015.12.018.